6th Targeted Protein Degradation Summit

Bruker’s Preconference Workshop features Ashok Dongre, BMS and Katherine Donovan, DFCI

Introduction

Visit us at our booth to learn how the 4D-Proteomics™ Ecosystem can help you master each step of targeted protein degradation for breakthrough discoveries. Find out how modern mass spectrometry is driving precise and effective targeted protein degradation, revolutionizing drug discovery.

Register for our preconference Workshop on October 30, 12:30 pm - 2:30 pm.

Successfully Implementing Mass Spectrometry-Based Proteomics for Targeted Protein Degrader Development

Mass spectrometry-based proteomics is an invaluable tool to simultaneously evaluate the effect of candidate degrader molecules on the protein of interest as well as the rest of the proteome. However, establishing a successful quantitative proteomics campaign requires setting up an entire pipeline starting with sample preparation and all the way through data interpretation.

Attend this workshop to:

Explore solutions for highly reproducible sample preparation and separation
Learn how 4D-Proteomics™ and trapped ion mobility (TIMS) improve the depth of screening campaigns
Discover software solutions to best quantify and identify proteins from data-independent acquisition experiments (dia-PASEF^®)
Leverage insights from the experience of academic and industry partners with the timsTOF ecosystem

Talks and Presenters:

Tools for the Implementation of Quantitative Proteomics Screening at Scale Guillaume Tremintin, Pharma/BioPharma Business Manager US, Bruker Scientific, San Jose, California, USA
Streamlined and Automated Proteomics Sample Preparation Workflow
Kara West, Head of US Sales, PreOmics, Billerica, Massachusetts, USA
Chemoproteomics Profiling Surveys the Degradable Proteome
Katherine Donovan, Ph.D., Lead Scientist, Dana Farber Cancer Institute, Boston, Massachusetts, USA
An Introduction to Bruker ProteoScape™
Jonathan Krieger, Ph.D., Bruker ProteoScape Head of Research, Bruker, Toronto, Canada
Expanding the Mass Spectrometry-Based Proteomics Toolbox for TPD Development for Early Discovery to the Clinics
Yuehan Feng, Ph.D., Senior Director of Application Sciences, Biognosys, Zurich, Switzerland
Proteomics at Scale: Whole Proteome Dynamics to Accelerate Degrader Selectivity, SAR and Pharmacology
Ashok Dongre, Ph.D., Senior Director & Head of Proteomics, Bristol-Myers Squibb, Boston, Massachusetts, USA
Shourjo Ghose, Ph.D., Proteomics Business Unit Manager, Bruker Scientific, Massachusetts, USA

Guest Speakers

Ashok Dongre, Ph.D., Senior Director & Head of Proteomics, Bristol-Myers Squibb, Boston, Massachusetts, USA

Katherine Donovan, Ph.D., Lead Scientist, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Register here

Topic Input value is invalid.

Contact Information

First Name Please enter your first name

Last Name Please enter your last name

Email Please enter a valid e-mail address

Company/Institution Please enter your Company/Institution

Are you a Customer?

Country or Area Please select your Country

State/Province Please select your State

Application Area

Current Situation

Marketing Consent:

Following of our interaction with you, Bruker Daltonics and its affiliates within the Bruker group (“Bruker”) would like to be able to stay in contact with you and inform you about the latest technological achievements and upcoming events as well as the products and services offered by Bruker. If you are interested in hearing from us in the future, we will need your consent in accordance with applicable data protection laws to be allowed to engage in marketing activities using your contact information. To view the promises that we make to you regarding your personal information, please view Bruker`s privacy policy. For questions related to privacy, please send your inquiry to privacy@bruker.com . If you prefer not to receive promotional e-mails from Bruker in the future, you can unsubscribe any time.

I agree that Bruker can use my contact information as described in this Marketing Consent form. Please accept the Terms and Conditions

Disclaimer:

As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regards to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.

*Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a non-governmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.

**A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.

Confirmation

I have read and understood

Thank you for registering.

For more information on high-throughput mass spectrometry for targeted protein degradation solutions by Bruker visit our Targeted Protein Degraders Application Page

For Research Use Only. Not for use in clinical diagnostic procedures.